Featured Research

from universities, journals, and other organizations

New pretargeted radioimmunotherapy for colorectal cancer

Date:
June 6, 2011
Source:
Society of Nuclear Medicine
Summary:
Results from a Phase 1 clinical trial for a cancer therapy show the potential to kill colorectal tumors with less destruction of healthy tissue. Further research could lead to the use of this radioimmunotherapy to eliminate residual cancer after surgery or as a standard treatment to keep tumors from returning or spreading to other organs.

Investigators at SNM's 58th Annual Meeting are presenting results from a phase 1 clinical trial for a cancer therapy that has the potential to kill colorectal tumors with less destruction of healthy tissue. Further research could lead to the use of this radioimmunotherapy to eliminate residual cancer after surgery or as a standard treatment to keep tumors from returning or spreading to other organs.

Related Articles


"Compared to the conventional way of guiding radiation to tumors with radiolabeled antibody, pretargeted radioimmunotherapy offers an attractive potential alternative because the delivery of therapeutic isotope is rapid and is separated from the long antibody delivery process, thereby reducing the harmful effects of radiation to the body, especially the bone marrow," says Rafke Schoffelen, MD, scientist of the study at Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. "This results in an optimal scheme with maximum therapeutic effect and minimal side effects."

According to the American Cancer Society it is estimated that more than 141,200 Americans in 2011 will be diagnosed with colorectal cancer, and 48,000 will die of the disease. Colorectal cancer is currently the third most commonly diagnosed cancer and the third leading cause of cancer death for both men and women across the country. This form of cancer develops in the colon and rectum, usually as a result of polyps, or abnormal growths, that extend from mucous membranes in the lower gastrointestinal tract. Once cancer is detected, the most common treatments are surgery and chemotherapy, but chemotherapy is associated with many side effects, some of them serious and lifelong. This pretargeted radioimmunotherapy is engineered to be an effective alternative with far fewer adverse effects.

In recent years the development of radioimmunotherapy has led to increasingly targeted cancer therapies that combine antibodies pinpointing specific physiological processes of the cancer and medical isotopes that deliver a dose of radiation to the cancer tissue. Pretargeted radioimmunotherapy takes this a step further by breaking the therapy into two phases. In the first phase, an antibody is infused that recognizes both an antigen from the tumor and the building blocks of proteins that serve as a vehicle for the radioisotope. When the antibody has cleared the rest of the patient's system, leaving only the tumor-bound antibody, a second phase is administered in the form of an injected small protein labeled with the medical isotope. The drug binds with the already tumor-bound antibody and delivers the radiation dose. The fraction of the drug that is not bound is quickly cleared from the rest of the body by the kidneys and out through the urine.

The objective of this study -- the first of its kind to treat patients with metastatic, or spreading, colorectal cancer with pretargeted radioimmunotherapy -- was to improve patients' prognosis without compromising their quality of life. It is conducted in collaboration with Garden State Cancer Center, Belleville, Immunomedics Inc. (NASDAQ: IMMU) and IBC Pharmaceuticals Inc. of Morris Plains, N.J., developers of the pretargeting mechanism and reagents.

First, patients were administered a test-cycle to map the path and predict the radiation dose of the subsequent therapy injection. The antibody, TF2, was infused followed by the small protein, IMP288, carrying a non-therapeutic isotope, 111In, which was measured by whole-body planar and single photon emission computed tomography imaging. Patients were then administered TF2 again, and the therapeutic isotope and agent 177Lu-IMP288. Research showed effective targeting of tumors and minimal healthy tissue damage, which could lead the way for further studies with higher or multiple dosing strategies and greater targeting of cancer tissue.


Story Source:

The above story is based on materials provided by Society of Nuclear Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Society of Nuclear Medicine. "New pretargeted radioimmunotherapy for colorectal cancer." ScienceDaily. ScienceDaily, 6 June 2011. <www.sciencedaily.com/releases/2011/06/110606131715.htm>.
Society of Nuclear Medicine. (2011, June 6). New pretargeted radioimmunotherapy for colorectal cancer. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2011/06/110606131715.htm
Society of Nuclear Medicine. "New pretargeted radioimmunotherapy for colorectal cancer." ScienceDaily. www.sciencedaily.com/releases/2011/06/110606131715.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins